

Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR⁺ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase 2b Trial

Hans Wildiers¹, Anne Armstrong², Eveline Cuypere³, Florence Dalenc⁴, Luc Dirix⁵, Steve Chan⁶, Frederik Marme⁷, Carolina P Schröder⁸, Jens Huober⁹, Francois P Duhoux¹⁰, Peter Vuylsteke¹¹, Agnes Jager¹², Etienne Brain¹³, Sherko Kuemmel¹⁴, Zsuzsanna Pápai¹⁵, Catharina Willemien Menke-van der Houven van Oordt¹⁶, Luca Perjesi¹⁷, Christian Mueller¹⁸, Chrystelle Brignone¹⁹, and Frederic Triebel¹⁹

¹Department of General Medical Oncology and Multidisciplinary Breast Centre, Leuven, Belgium. ²The Christie NHS Foundation Trust, Manchester, United Kingdom. ³AZ Sint-Jan Burgge-Oostende AV, Ruddershove, Belgium. ⁴Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France. ⁵GZA ziekenhuizen campus Sint-Augustinus, Antwerp, Belgium. ⁶Nottingham Cancer Clinical Trials Team (NCCTT), Nottingham, United Kingdom. ⁷National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg, Germany. ⁸Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam and University Medical Center Groningen, the Netherlands. ⁹Breast Center Cantonal hospital St Gallen, Switzerland and Department of Gynaecology, University of Ulm, Germany. ¹⁰Cliniques universitaires Saint-Luc, UCLouvain, Brussels, Belgium. ¹¹CHU UCL Namur, Site Sainte-Elisabeth, UCLouvain, Namur, Belgium. ¹²Erasmus MC Cancer Institute, Rotterdam, The Netherlands. ¹³Institut Curie-Hôpital René Huguenin, Saint-Cloud, France. ¹⁴Breat Unit, KEM Kliniken Essen-Mitte, Essen, Germany, Charité –

Universitätsmedizin Berlin, Department of Gynecology with Breast Center, Berlin, Germany. ¹⁵MH Egészségügyi Központ Onkológiai Osztály, Budapest, Hungary. ¹⁶Amsterdam University Medical Centers, Location VUmc, Amsterdam, The Netherlands. ¹⁷Immutep, Budapest, Hungary. ¹⁸Clinical Development, Immutep, Berlin, Germany. ¹⁹Research & Development, Immutep, Saint-Aubin, France.

Running Title: Paclitaxel and Eftilagimod Alpha in Metastatic Breast Cancer

Keywords: Biomarker; Breast Cancer; Clinical Trial Phase 2; Eftilagimod Alpha; Immunotherapy, Active; Lymphocyte Activation; Paclitaxel

Financial Support: This study was funded by Immutep S.A.S.

Corresponding Author:

Frédéric Triebel, MD, PhD

Immutep S.A.S.
Parc Les Algorithmes
Bâtiment 7- Le Pythagore
Route de l'Orme - RD128
91190 Saint-Aubin, France
+33-660916593
frederic.triebel@immutep.com

Authors' Disclosures: **H. Wildiers** participated in data safety monitoring or advisory boards for AstraZeneca, AbbVie, Daiichi Sankyo, Eisai, KCE, Lilly, Novartis, Orion Corporation, Pfizer, PSI Cro AG, Puma Biotechnology, Roche, Sirtex, MSD, Augustine Therapeutics, and E Squared Communications. **A. Armstrong** reports educational grants from AstraZeneca and travel support from MSD and Gilead, participated in advisory boards for MSD and Gilead, serves as clinical lead for the RCOG Pregnancy

and Breast Cancer Guideline update, and holds stocks with AstraZeneca outside the submitted work. **F. Dalenc** participated in advisory boards for AstraZeneca, Pfizer, Daichi, Gilead, Lilly, Novartis and Seagen; and travel support from Daichi, Pfizer, Novartis, and Gilead. **L. Dirix** participated in an advisory board for the AIPAC study. **F. Marme** reports consulting fees from AstraZeneca, Eisai, Genomic Health, Gilead, GSK/Tesaro, and Pfizer; honoraria from Agendia, AstraZeneca, Clovis, Eisai, Eli Lilly, Genomic Health, GSK/Tesaro, Immunomedis/Gilead, MSD, Myriad Genetics, Novartis, Pfizer, PharmaMar, Pierre-Fabre, Roche, and Seagen; and travel support from AstraZeneca, Gilead Sciences, Pfizer, and Roche and participated in data safety monitoring or advisory boards for Amgen and Pallesos. **C.P. Schröder** reports research support from Gilead, Siemens, Pfizer outside the submitted work. **J. Huober** reports grants from Celgene, Novartis and Lilly; consulting fees from AbbVie, AstraZeneca, Celgene, Gilead, Lilly, MSD, Novartis, Pfizer, Roche, and Seagen; honoraria from AbbVie, AstraZeneca, Celgene, Daiichi, Gilead, Lilly, MSD, Novartis, Pfizer, Roche, and Seagen; and travel support from Celgene, Daiichi, Novartis, Pfizer and Roche outside the submitted work. **FP Duhoux** reports a postdoctoral research grant from Fondation belge contre le cancer, consulting fees from Amgen, AstraZeneca, Daiichi Sankyo, Eli Lilly, Gilead Sciences, MSD, Novartis, Pfizer, Pierre Fabre, Roche and Seagen; and travel support from Amgen, Daiichi Sankyo/AstraZeneca, Gilead Sciences, Pfizer, Roche and Teva outside the submitted work. **P. Vuylsteke** received honoraria from Novartis, MSD, and Roche outside the submitted work. **E. Brain** reports consulting fees from Pfizer and Sandoz; honoraria from Eli Lilly, Pfizer and Seagen; and travel support from Pfizer and Sandoz and participated in the data safety monitoring board from

Daiichi DESTINY-Breast05 outside the submitted work. **S. Kuemmel** reports consulting fee from Lilly and MSD; honoraria from AstraZeneca, Lilly and Pfizer; and travel support from Daiichi Sankyo, Lilly, and Roche; participated in data safety monitoring or advisory boards for Agendia, Amgen, AstraZeneca, Daiichi Sankyo, Exact Science, Gilead Science, Hologic, Novartis, Pfizer, PFM Medical, MSD, Roche, Seagen, and SonoScape; and has a role in the leadership board of AGO, and WSG ESMO outside the submitted work. **C. W. Menke-van der Houven van Oordt** reports consulting fees from Lilly; research support from Pfizer, AstraZeneca, and G1 Therapeutics; and travel support from Daiichi Sankyo. **L. Perjesi** holds employment with Immutep GmbH and stocks with Immutep Ltd and participated in the data safety monitoring boards of Immutep-sponsored trials. **C. Mueller** holds employment with Immutep GmbH and stocks with Immutep Ltd. **C. Brignone** holds employment with Immutep SAS and stocks with Immutep Ltd and has one patent pending or issued and others planned. **F. Triebel** holds employment with Immutep SAS and stocks with Immutep Ltd, serves as a board member of Immutep Ltd, and has one patent pending or issued and others planned. **E. Cuypere, S. Chan, A. Jager and Z. Pápai** declare no potential conflicts of interest.

Category: *Clinical Trials: Immunotherapy*

Word count: 4501/5000 (text), 250/250 (abstract)

Running Title: 60/60 characters

Translational Relevance: 145/150 words

Tables and Figures: 5/6

TRANSLATIONAL RELEVANCE (145/150 words)

Despite major advances in early breast cancer treatment the need for novel therapies for metastatic breast cancer (MBC) after failure of endocrine-based therapies (ET) remains high. Eftilagimod alpha (efti), a soluble LAG-3 protein, is a potent antigen-presenting cell (APC) activator. The activation of dendritic cells by efti could restore the deficient T-cell priming reported in poorly immunogenic HR⁺ MBC tumors. The phase 2b, multicenter, randomized AIPAC trial examined a chemo-immunotherapy approach using efti versus placebo in women with HR⁺ MBC receiving weekly paclitaxel after failure of ET-based therapy. Median OS was significantly improved for efti in predefined subgroups. Levels of circulating monocytes, CD4⁺, and CD8⁺ T cells together with relevant Th1 biomarkers significantly increased in the efti arm, and CD4⁺ and CD8⁺ cell numbers were linked to improved overall survival. These findings support a further prospective investigation of efti in patients with ET-resistant HR⁺ MBC.

ABSTRACT (250/250 words)

Purpose

Eftilagimod alpha (efti), a soluble LAG-3 protein and MHC class II agonist, enhances innate and adaptive immunity. AIPAC evaluated safety and efficacy of efti plus paclitaxel in patients with predominantly endocrine-resistant, hormone receptor–positive, HER2-negative metastatic breast cancer (ET-resistant HR⁺ HER2[−] MBC).

Experimental Design

Women with HR⁺ HER2[−] MBC were randomized 1:1 to weekly intravenous paclitaxel (80 mg/m²) and subcutaneous efti (30 mg) or placebo every 2 weeks for six 4-week cycles, then monthly subcutaneous efti (30 mg) or placebo maintenance. Primary endpoint was progression-free survival (PFS) by blinded independent central review. Secondary endpoints included overall survival (OS), safety/tolerability, pharmacokinetics/pharmacodynamics, and quality of life. Exploratory endpoints included cellular biomarkers.

Results

114 patients received efti and 112, placebo. Median age was 60 years (91.6% visceral disease, 84.1% ET-resistant, 44.2% with previous CDK4/6 inhibitor treatment). Median PFS at 7.3 months was similar for efti and placebo. Median OS was not significantly improved for efti (20.4 vs. 17.5 months; HR, 0.88; *P* = 0.197), but became significant for predefined exploratory subgroups. EORTC QLQC30-B23 global health status was sustained for efti but deteriorated for placebo. Efti increased absolute lymphocyte, monocyte and secondary target cell (CD4, CD8) counts, plasma IFN-γ and CXCL10 levels.

Conclusions

Although the primary endpoint, PFS, was not met, AIPAC confirmed expected pharmacodynamic effects and demonstrated excellent safety profile for efti. Overall survival was not significantly improved globally (2.9-month difference), but was significantly improved in exploratory biomarker subgroups, warranting further studies to clarify efti's role in patients with ET-resistant HER2⁺ MBC.

INTRODUCTION

Although most patients with breast cancer are diagnosed with early-stage disease, 6%–10% initially present with metastatic breast cancer (MBC), and an additional 20%–30% will later develop MBC (1). Of these, approximately two-thirds have estrogen and/or progesterone receptor–positive, HER2-negative (HR⁺ HER2[−]) disease (2). The approval of cyclin-dependent kinase (CDK)4/6 inhibitors (CDK4/6i) in combination with endocrine therapy (ET) in 2015 set a new standard of care, eventually displacing ET alone or chemotherapy as the preferred first-line treatment option for most patients (3,4). Although this extends survival, progression on CDK4/6i and endocrine therapy almost inevitably occurs through a variety of resistance mechanisms (4,5). Progression on CDK4/6i is frequently associated with a more aggressive phenotype, for which patients are often subsequently treated with chemotherapy (6,7). In this post-CDK4/6i/ET treatment setting, chemotherapy benefits are limited, with a median treatment duration of 4–5 months and median overall survival (OS) of approximately 1–2 years (6,7), and immunotherapeutic approaches have so far proven challenging (8). Most, especially luminal, breast cancers are associated with low levels of T-cell infiltration, resulting in what has been termed an immunologically silent, or "cold," tumor (9), for which single-agent checkpoint inhibitors have generally proven ineffective (8). Thus, the paradigm shift induced by the introduction of frontline CDK4/6i/ET highlights the need for more effective and safe chemotherapy-based treatment approaches for patients with MBC.

The role of adaptive immune response in chemotherapy effectiveness is well established (10,11). Priming CD8⁺ T-cells is a prerequisite for their tumor-killing

property. Defects in T-cell priming, rather than T-cell exhaustion or lack of tumor penetration, may contribute to the low levels of T-cell infiltration observed in MBC (8,9,12). Thus, enhancing T-cell priming by activated and matured dendritic cells (DCs) may help restore immunological response in the presence of tumor neoantigens. Chemotherapy-induced tumor cell apoptosis provides antigens used by antigen-presenting cells (APCs) for CD8⁺ T-cell priming. This ultimately leads to increased cytotoxic T-cell infiltration into tumors (Supplementary Fig. S1) (13). The resulting immunoadjuvant effect suppresses tumor growth and is key to long-term survival (10,14,15). Lymphocyte activation gene-3 (LAG-3) protein is a dimeric cell surface receptor expressed on activated T cells that functions as an inhibitory checkpoint molecule in multiple cancers (16,17). In addition, soluble LAG-3 levels in serum have been correlated with lower risk of relapse in patients with breast cancer (18). Eftilagimod alpha (efti; IMP321) is a unique recombinant soluble LAG-3 protein that mimics the structure of the dimeric LAG-3 receptor expressed on T-cell membranes (19). Efti acts as a major histocompatibility complex (MHC) class II agonist, triggering activation of APCs and then secondary T-cell proliferation and activation, which results in a sustained immune response in preclinical and clinical studies (19-22).

The Active Immunotherapy PAClitaxel (AIPAC; NCT02614833) study was designed to investigate the efficacy and safety of efti plus paclitaxel versus placebo plus paclitaxel in patients with predominantly ET-resistant HR⁺ HER2⁻ MBC eligible to receive chemotherapy (23). Here, we report the final results from this randomized, double-blind, placebo-controlled phase 2b study.

MATERIALS AND METHODS

Study design

Detailed methods for AIPAC and results of the run-in stage of the study have been described (23,24). Briefly, this was a multicenter, placebo-controlled, double-blind randomized study comparing efti plus paclitaxel with placebo plus paclitaxel in women with HR⁺ HER2⁻ MBC. Patients were randomized 1:1 to receive intravenous paclitaxel (80 mg/m² on days 1, 8, and 15) followed by either subcutaneous efti at the recommended phase 2 dose of 30 mg or subcutaneous placebo on days 2 and 16 of each 4-week cycle for 6 cycles or until progression, withdrawal of consent, or death. Randomization was done using an interactive web-based response system stratified by Eastern Cooperative Oncology Group (ECOG) performance status (0 or 1) via permuted blocks. Patients with a response or stable disease (SD) who completed ≥4 cycles were allowed to continue into the maintenance phase, thereupon receiving efti alone (30 mg subcutaneous) or placebo every 4 weeks for up to 12 cycles (Supplementary Fig. S2A). The trial was registered on clinicaltrials.gov (NCT02614833) and was conducted according to current Good Clinical Practice guidelines and the Declaration of Helsinki. The protocol was reviewed by independent ethics committees at all participating institutions, and all patients provided written informed consent.

Patients

Eligible patients were females 18 years or older with HR⁺ HER2⁻ MBC who were indicated to receive chemotherapy with weekly paclitaxel. ECOG performance status of 0 or 1, and measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 were required. Individuals with prior MBC chemotherapy, inflammatory

carcinoma, those requiring systemic corticosteroid or other immunosuppressive therapy, and candidates for trastuzumab or other HER2-targeted treatment were excluded. Prior endocrine-based therapy was allowed.

Outcomes

The primary objective was to determine the efficacy of efti plus weekly paclitaxel compared with placebo plus weekly paclitaxel. The primary endpoint was difference in progression-free survival (PFS) as determined by blinded independent central review (BICR) and by local assessment, both using RECIST 1.1 criteria. Secondary endpoints included overall survival (OS), adverse events (AEs) graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) V4.03, time to next treatment (TTNT), objective response rate (ORR), patient quality of life (QoL), and antidrug antibody (ADA) levels. Exploratory endpoints included blood immune cell phenotypes (e.g., monocyte numbers and activation, CD8⁺ T-cell numbers), assessment of soluble T helper (Th)1 biomarkers, and tumor biomarkers. Whole blood and plasma samples were collected to monitor circulating immune cell subsets and Th1 biomarkers, respectively, before the start of the treatment on cycle 1 day 1, predose on cycle 4 day 1, at the maintenance start (i.e., 13 days after the previous efti injection to detect minimal residual effects) and at the end of treatment visit from a subset of patients in the randomized stage (67 and 49 patients for cellular and soluble biomarkers, respectively). Biomarkers were also monitored in patients in the run-in stage. Additional samples from run-in patients were collected to assess pharmacokinetics (PK) at early time points after 6 mg and 30 mg efti doses. Ex vivo absolute counts of blood cell subsets were determined in whole blood using a lyse-no-

wash single-platform cytometry procedure and fluorescent staining antibody mixtures (see Supplementary Methods for details). Th1 biomarkers (IFN- γ and CXCL10) were measured using an electrochemiluminescence assay. Absolute lymphocyte count (ALC), monocytes and neutrophils were obtained locally from whole blood samples collected predose over the treatment period.

Radiological assessments were conducted at 8-week intervals from date of randomization until week 73 and thereafter at 12-week intervals. Physical examinations were conducted on day 1 of each cycle. Patient quality of life (QoL) was measured using the European Organisation for Research and Treatment of Cancer QoL Cancer-Specific Version, Breast Cancer Specific Version (EORTC QLQC30-BR23), and the EuroQol Research Foundation Health-Related Quality of Life at regular intervals (baseline, weeks 13, 25, 49, and at end of treatment). Retrospective central assessment of breast cancer subtypes was performed using PgR and Ki67 index according to St Gallen International Expert Consensus guidelines (25).

Statistical analysis

Both the safety population and the full analysis set (FAS) consisted of all randomized patients who received ≥ 1 dose of study drug. Safety data, ADA data, and items on QoL scales were analyzed descriptively. The FAS population was the primary population for analyses of efficacy endpoints.

The null hypothesis of no PFS difference between treatment arms was tested using a log-rank test with a 1-sided alpha of 0.05 stratified by ECOG performance status (0 vs. 1). Assuming PFS values of 12 months in the efti plus paclitaxel arm and 8 months in the placebo plus paclitaxel arm, 113 patients per arm would provide 80%

power to detect a hazard ratio (HR) of 0.667. PFS and other time-to-event endpoints were estimated using the Kaplan-Meier method. Differences in ORR between randomized arms were tested using Cochran-Mantel-Haenszel testing at a 2-sided alpha of 0.05, stratified by ECOG performance status (0 vs. 1). Poor prognostic markers using baseline characteristics were analyzed in a multivariate Cox model using backward selection. Biomarkers between group comparison was performed by nonparametric rank-sum 2-sided Wilcoxon test. In-between group comparison of posttreatment values to baseline value was tested using matched-paired rank-signed Wilcoxon test. Spearman correlation coefficient was used to evaluate the relationship between biomarkers and clinical outcome parameters. SAS version 9.4 software (SAS software, Cary, NC) or SAS JMP version 12.0.1 software was used for the analyses.

Data availability statement

The data generated in this study are available from the corresponding author pursuant to reasonable request and approval from study sponsor (Immutep S.A.S) according to available guidelines at time of request. This access restriction is in place to safeguard patient privacy.

RESULTS

Patient population

Results of the open-label safety run-in phase assessing the safety, tolerability, PK, and immune response of efti plus paclitaxel have been previously reported (24). The present report focuses on the randomization phase results. Between January 2017 and July 2019, AIPAC screened 277 patients at 32 sites in Belgium, the Netherlands, Germany, France, the United Kingdom, Hungary, and Poland. A total of 227 patients were enrolled, of which 114 were randomized to efti plus paclitaxel and 113 were randomized to placebo plus paclitaxel. One patient randomized to the latter received no study treatment and was excluded from analysis. Baseline characteristics were well-balanced between treatment groups (**Table 1**). The median age was 60 years (range, 24–87) and the majority of patients (61.5%) had ECOG performance status 0. Patients had late-stage disease (91.6% visceral, 69.2% elevated lactate dehydrogenase). Most patients (73.9%) had received 1 or 2 prior systemic therapies for MBC, and 84.1% were endocrine resistant (26). Notably, at the time the study began (January 2017), CDK4/6i (in combination with ET) were not routinely used. As a result, only 44% of patients had used prior CDK4/6i.

Efficacy outcomes

In the efti and placebo arms, 60 (52.6%) and 54 (48.2%) patients, respectively, completed the 6 cycles of treatment (Supplementary Fig. S2B). At the cutoff date of May 14, 2021, the median follow-up time was 19.7 months (range, 0.7–47.6) in the efti arm and 16.9 months (range, 0.9–48.7) in the placebo arm. Median treatment duration was

6.2 months and 5.9 months, respectively, and the mean paclitaxel dose intensity during chemoimmunotherapy was 93.1% and 92.8%, respectively.

Median PFS by BICR, the primary endpoint, was 7.3 months (95% CI, 6.6–7.5) in the efti arm and 7.3 months (95% CI, 5.5–7.5) in the placebo arm (HR 0.93 [95% CI, 0.67–1.30]; $P = 0.341$) (**Fig. 1A**). PFS by investigator assessment provided similar results. Median OS was 20.4 months (95% CI, 14.3–25.1) in the efti arm and 17.5 months (95% CI, 12.9–21.8) in the placebo arm (HR, 0.88; 95% CI, 0.64–1.19; $P = 0.197$) (**Fig. 1B**). At 12 and 24 months, the proportion of surviving patients was 65% (95% CI, 55–73) and 43% (95% CI, 34–52) for efti and 63% (95% CI, 53–71) and 37% (95% CI, 28–46) for placebo, respectively.

A total of 107 patients (93.9%) and 106 patients (94.6%), respectively, were evaluable for response. The ORR by BICR was 51.4% (95% CI, 42–61) in the efti arm and 40.6% (95% CI, 31–51; $P = 0.118$) in the placebo arm with disease control rates of 90.7% (efti) and 80.2% (placebo) (Supplementary Table 1).

Median TTNT was 7.7 months and 6.9 months for efti and placebo, respectively. The median time to objective response (based on BICR) for subjects in the efti group (2.1 months [95% CI, 1.87–3.58]) was lower than subjects in the Placebo group (3.6 months [95% CI, 1.94–3.71]). Post-study treatment was similar in both arms, with 86% and 90.2% of patients in the efti and placebo groups, respectively, receiving any post-study systemic anticancer therapy. The majority of these patients (70.2% and 76.8%, respectively) received chemotherapy.

Preplanned univariate analysis identified four patient subgroups for which PFS, OS and/or ORR were significantly improved in the efti arm: younger than 65 years, low

baseline monocytes ($<0.25 \times 10^9$ cells/L), no prior taxane therapy, and luminal B disease (**Fig. 2A-B**, Supplementary Fig. S3 and S4). In addition, an exploratory post hoc univariate analysis associated the subgroups high (>3.65 ; cut-off determined by its median) neutrophil to lymphocyte ratio at baseline and shorter time (<5 years, cut-off determined by its approximative median) since diagnosis with significantly improved OS (**Fig. 2B** and Fig. S4). An exploratory multivariate analysis to identify independent poor prognostic markers regardless of the therapy received associated prior CDK4/6i therapy with decreased PFS (HR, 1.65; $P = 0.001$) and OS (HR, 1.37; $P = 0.072$) among all randomized patients. When analyzed by treatment arm, prior CDK4/6i treatment had a larger negative impact on OS in the placebo arm (median OS reduced from 20.4 to 14.9 months) than in the efti arm (median OS reduced from 21.9 to 20.2 months).

At 6 months, global health status per the EORTC QLQC30-B23 questionnaire had significantly deteriorated relative to baseline among patients in the placebo arm (mean change from baseline -8.0 [95% CI, -14.47 to -1.50]) but was maintained at a baseline level in the efti arm (mean change from baseline -0.3 [95% CI, -6.52 to 5.88]) (Supplementary Fig. S5).

Safety

Any treatment-emergent AEs (TEAEs) grade ≥ 3 were reported in 68.4% and 65.2% of patients in the efti and placebo arm, respectively. The majority of TEAEs occurred at similar rates in both treatment arms (**Table 2**). Grade ≥ 3 anemia, though uncommon, was more frequent in the efti arm (6.1% vs. 0.9%). Grade ≥ 3 gamma-glutamyl transferase increase (20.2% vs. 29.5%), hypophosphatemia (0.9% vs. 8.0%)

and any-grade peripheral edema (7.0% vs.17.0%) were more common in the placebo arm.

Discontinuations due to AEs during chemo-immunotherapy were infrequent and similar between arms (6.1% for efti; 8.0% for placebo), and no patient discontinued maintenance therapy due to an AE. TEAEs leading to discontinuation of efti or placebo (5.3% and 6.3% in the efti and placebo arms, respectively) or discontinuation of efti + paclitaxel or placebo + paclitaxel (7.0% and 10.7%, respectively) were infrequent and occurred at similar rates in both arms. TEAEs leading to death occurred at similar frequency in the efti and placebo arm (2.7% versus 1.8%) and were generally associated with progression of the underlying disease or paclitaxel toxicity.

Any kind of local injection-site reactions were notably more common in the efti arm (65.8% any grade) than in the placebo arm (11.6% any grade). None of them were serious, and none led to efti discontinuation. There were 3 (2.6%) immediate systemic hypersensitivity reactions to efti (2 of grade 4, 1 of grade 2) in the efti arm which occurred later in the treatment course (after 4, 5, and 9 efti injections).

Recurrent reactions indicating systemic inflammatory responses occurring shortly after efti injection were reported in 13 (11.4%) patients in the efti arm and 1 (0.9%) in the placebo arm and included, for example, chills, pyrexia, and influenza-like illness. All reactions were of mild or moderate severity.

Pharmacokinetics, Pharmacodynamics and Immunogenicity

Pharmacokinetic analyses conducted during the run-in phase (6-mg and 30-mg subcutaneous doses) indicated a dose-proportional increase in exposure parameters

($C_{\max}$, AUC) with relatively high inter-subject variability, consistent with subcutaneous administration of a large protein (160 kDa) requiring lymphatic transport. At the 30-mg dose, $T_{\max}$ was found between 2 and 24 hours and decreased rapidly thereafter (Supplementary Fig. S6). No accumulation was observed after repeated dosing. Pharmacodynamic measurements at day 13 post-dose reflect the residual effect of efti on the immunological status, as efti is no longer present in blood at any detectable level. Thus, any immunostimulatory effect observed at that time would indicate a long-term sustainable innate and adaptive response and subsequent efti injection is expected to boost these responses again.

In the subset of patients ($n = 67$, baseline characteristics presented in Supplementary Table 3) participating in cellular biomarker assessment, significant increases in the number of circulating primary target cells (monocytes and myeloid DCs [mDCs]) relative to baseline were observed in the efti arm and, to a lesser extent, in the placebo arm at all postbaseline measured timepoints. Mean fold changes from baseline were higher in the efti arm compared with placebo at all visits, reaching significance at the final timepoint (3.55 vs. 2.07; $P = 0.04$ and 4.29 vs. 1.55; $P = 0.025$ for monocytes and mDC respectively). Increases in secondary target cells (T cells) were observed in the efti arm compared with placebo. $CD8^+$ T cell levels were significantly higher at all postbaseline timepoints ($P = 0.006$ at 3 months; $P = 0.047$, 6 months), whereas baseline values showed no significant difference ($P = 0.061$) (**Fig 3A**). The number of $CD8^+$ T cells at 6 months positively correlated with OS in patients treated with 30 mg efti ($Rho = 0.58$; $P = 0.007$), but not in those treated with placebo ($Rho = -0.16$; $P = 0.535$).

A weaker but significant correlation was already noted at 3 months in efti group (Rho = 0.37; $P = 0.041$), but not in placebo group (Rho = -0.07; $P = 0.722$) (**Fig. 3B**).

In available data sets compiled from all participants in immune monitoring, maximal postbaseline CD8⁺ T-cell levels (obtained from sampling collected weeks after the previous efti or placebo dosing) were significantly ($P = 0.025$) higher in patients with median or above-median OS only in patients treated with efti (Supplementary Fig. S7A). CD4⁺ T-cell levels were significantly higher in patients with OS at or above the median OS in patients treated with efti ($P = 0.002$) and with placebo ($P = 0.023$), and at baseline in the placebo arm ($P = 0.048$) (Supplementary Fig. S7B).

Maximal postbaseline fold increases from baseline were higher in the efti arm for monocytes, mDC, and activated CD4⁺ and CD8⁺ T cells, reaching significant differences for monocytes ($P = 0.009$) and activated CD8⁺ T cells ($P = 0.020$) (Supplementary Fig. S7C). Higher maximal postbaseline fold change of activated CD4⁺ T cells ($P = 0.013$) and activated CD8⁺ T cells ($P = 0.013$) were significantly associated with median or above-median OS in the efti arm. Activated CD4⁺ T cells correlated with this also in the placebo arm at the significance limit ($P = 0.052$). (Supplementary Figure S7D).

In the full randomization subject set, ALCs demonstrated early and sustained increases in the efti arm, with the effect being larger during maintenance with significant differences to placebo arm at two time periods (not shown). Increased ALCs were significantly associated with OS times at or above median in patients in the efti arm over the treatment period, but not the placebo arm (**Fig. 3C**). In the efti arm, the subgroup of patients displaying an early (within the first two cycles) ALC increase from baseline by $0.2 \times 10^9/\text{L}$ of blood or more had a median OS of 29.2 months (95% CI, 20.2–37.3)

while in the subgroup with lower increase or decrease in ALC, median OS was 14.2 months (95% CI, 10.1–21.4) (HR 0.52; 95% CI, 0.32-0.83; $P = 0.003$). (**Fig. 3D**). A gain of 15 months in OS was then observed between the ALC change subgroups in the efti arm. There was no difference in OS based on ALC change subgroups in the placebo arm (HR, 1.17; 95% CI, 0.74–1.86; $P = 0.246$) (**Fig. 3E**).

IFN- γ and CXCL10 levels increased significantly relative to baseline at 6 months in the efti group ($P = 0.014$ and $P = 0.02$), but not in the placebo group. At all timepoints, the fold changes from baseline of CXCL10 were higher in efti arm compared with placebo, reaching significant levels at the last timepoint (2.31 vs. 1.15; $P = 0.038$).

Non-neutralizing anti-efti antidrug antibodies (ADAs) were found in 85.5% of efti patients, with 64.2% developing ADAs within 4 weeks of the first dose. ADAs, however, were non-neutralizing and had no medically relevant effect on exposure, safety, or efficacy.

DISCUSSION

In the AIPAC study, the efficacy and safety of efti versus placebo with a weekly paclitaxel were evaluated in patients with ET-resistant HR⁺ HER2⁻ MBC eligible to receive chemotherapy. Consistent with its immunostimulatory mechanism of action, a 30-mg subcutaneous dose of efti was associated with a sustained significant increase of primary (monocytes and DCs) and secondary target cells (T cells) in addition to Th1 markers in peripheral blood. Levels of on-treatment CD8⁺ T cells were linked to improved overall survival. Increased ALC levels in efti-treated patients were present during both the chemoimmunotherapy and maintenance phases and significantly correlated with improved OS among patients in that arm. Early increase in ALC correlated with a significantly longer OS in efti arm and a lower risk of death (HR, 0.54). Immunomonitoring of efti as a systemic APC activator can then be easily performed through repeated minimally-invasive liquid biopsies (blood samplings).

Although the primary endpoint, median PFS, was not met (both medians, 7.3 months; $P = 0.341$), the proportion of progression-free patients were numerically higher for the efti arm during the 6-month chemoimmunotherapy period (**Fig. 1A** and Supplementary Table 4A), the PFS advantage subsequently being lost during maintenance when chemotherapy was stopped. Mechanistically, these observations are consistent with the adjunctive effects of improved T-cell priming, for which efficacy is dependent upon the availability of tumor neoantigens supplied by chemotherapy-induced tumor cell killing. In this mechanism, chemotherapy cooperates with APC activation to transport tumor cell apoptotic debris-derived antigens to the lymph nodes for presentation to T cells. Conceivably, a longer course of chemotherapy could extend

the efti PFS advantage observed during chemoimmunotherapy. It is also possible that the reduced efti dosing frequency during maintenance (every 4 weeks) may not have been sufficient for sustaining benefit because the duration of efti pharmacodynamic effects beyond 13 days was not examined in this study.

There was a non-statistically significant trend for improvement in OS in the overall efti arm (median 20.4 months vs. 17.5 months; $P = 0.197$). Exploratory subgroup analyses associated a significant efti efficacy benefit in patients <65 years, with low monocytes at baseline, with luminal B disease, high neutrophil-lymphocyte ratio at baseline, no prior taxane therapy, and with <5 years since diagnosis. These findings are consistent with the mechanism of action of efti. Older patients with MBC are known to have a reduced number of CD8⁺ T cells (27). In these patients, activation by efti would be expected to produce less of an effect. In patients with low monocytes at baseline, the ability of efti to boost numbers of primary and secondary target cells may also promote efficacy.

Prior CDK4/6i therapy, representing 44.2% of this patient population, was associated with a lower median OS in the placebo arm when compared with no prior treatment (20.4 to 14.9 months). Multivariate analysis showed that prior CDK4/6i therapy was associated with a higher risk of progression (HR, 1.65) and death (HR, 1.37) compared with patients without prior CDK4/6i. This is the first time to our knowledge that this poor prognostic effect of prior CDK4/6i on PFS of subsequent treatment and on survival, independent of factors such as time since diagnosis and number of metastatic sites at study entry, has been shown in a randomized setting. Interestingly, median OS was almost unchanged with efti in those patients previously

treated with CDK4/6i (20.2 vs. 21.9 months), suggesting a possible protective effect of efti in this population. Approximately one-half of AIPAC patients were enrolled before CDK4/6i in combination with ET displaced chemotherapy as the standard of care in first-line HR⁺ HER2⁻ MBC. In the evolving treatment landscape, with chemotherapy reserved for later lines, a shorter survival benefit for chemotherapy than the approximately 25-26 months reported in older trials such as E2100 (28) and MERIDIAN (29), both of which had less heavily pretreated patient populations than AIPAC, is to be expected. Thus, the use of efti plus chemotherapy in later lines appears worthy of further study. For further development, it is noteworthy that QoL did not drop at 6 months as it did in the placebo arm. This is important as overall survival and QoL (the latter being better with efti compared with placebo) are considered as priority outcomes in the European Society of Medical Oncology Magnitude of Clinical Benefit Scale (30).

Adverse events for efti plus paclitaxel were dominated by the known toxicities associated with the latter in patients with breast cancer. Local injection site reactions (any grade, 65.8%) up to grade 2, immediate hypersensitivity reactions (any grade, 2.6%), and various mild-to-moderate severity systemic inflammatory responses (any grade, 11.4%) were the main TEAEs attributed to efti. Mechanistically, local injection site reactions may result from transitory high concentrations of efti in the dermis and the hypodermis after injection leading to strong activation of MHC II⁺ Langerhans cells and subcutaneous dendritic cells along with local inflammation.

This study had several limitations. As enrollment in AIPAC spanned a period in which there were 2 separate standards of care for ET-based therapies of HR⁺ HER2⁻ MBC—a situation that could not be foreseen when the study was designed—these

results could be viewed as the collective analysis of 2 different patient populations, potentially confounding the interpretation of results. Sample size was also limited in this phase 2b trial, limiting the interpretation of final OS data.

In conclusion, results from AIPAC confirmed the expected pharmacodynamic effects of efti in sustainably stimulating the innate and adaptive immune response over long periods of time and demonstrated that it was well-tolerated in combination with paclitaxel in patients with HR⁺ HER2⁻ MBC. Although the primary endpoint of median PFS was not met, efti displayed a numerically, although not statistically significant, improvement in OS and significant clinical benefit in subgroups consistent with its mechanism of action. Efti was well tolerated and warrants further study to clarify its efficacy in combination with chemotherapy in this patient population. Based on the results of AIPAC, a follow-up study (AIPAC-003; NCT04252768) was initiated with a couple of key adaptations: if tolerated, paclitaxel will not be stopped after 6 cycles, efti will be more frequently administered during in the maintenance phase (remaining at every 2 weeks). Most importantly, based on its excellent safety, the dose of efti will be increased to 90 mg. We saw in AIPAC a meaningful increase in many of the measured biomarkers within about 60% of efti-treated patients. We have reasonable belief that a higher dose can increase this proportion and thus increase efficacy as well. An extensive biomarker program is planned for AIPAC-003 in the potential phase 3 part of AIPAC-003.

AUTHOR CONTRIBUTIONS

Conceptualization: FT, CM, LP, CB

Resources: JH, CWMHO, PV, HW, AA, FD, EB, SK, EC, SC, AJ, ZP, CS

Data curation: CM, CB, LP

Formal analysis: CM, LP, CB

Supervision: CM

Funding acquisition: FT

Investigation: all authors

Visualization: CM, CB

Methodology: FT, CM, LP, CB

Project administration: CM, PV, HW, AA, FD, EB, SK, EC, SC, AJ, ZP, JH, CWMHO

Writing, reviewing, and editing: all authors

ACKNOWLEDGMENTS

We thank the patients, their supporters, and the investigators at the various study centers. We also thank Dr. Jean-Philippe Jacquin and Dr Jill Wagemans for participating as investigators in this trial. Medical writing and editorial assistance were provided, under the direction of the authors, by Robert Rydzewski, MS, and Miriam Cohen, PhD, ISMPP CMPP, of Bio Connections, LLC (Chicago, IL), supported by Immutep.

REFERENCES

1. Wang R, Zhu Y, Liu X, Liao X, He J, Niu L. The Clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer. *BMC Cancer* 2019;**19**(1):1091 doi 10.1186/s12885-019-6311-z.
2. Twelves C, Bartsch R, Ben-Baruch NE, Borstnar S, Dirix L, Tesarova P, *et al.* The Place of Chemotherapy in The Evolving Treatment Landscape for Patients With HR-positive/HER2-negative MBC. *Clinical Breast Cancer* 2022;**22**(3):223-34 doi 10.1016/j.clbc.2021.10.007
3. Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, André F, *et al.* 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). *Ann Oncol* 2020;**31**(12):1623-49 doi 10.1016/j.annonc.2020.09.010.
4. D'Amico P, Cristofanilli M. Standard of Care in Hormone Receptor-Positive Metastatic Breast Cancer: Can We Improve the Current Regimens or Develop Better Selection Tools? *JCO Oncol Pract* 2022;**18**(5):331-4 doi 10.1200/OP.21.00707.
5. Scheidemann ER, Shajahan-Haq AN. Resistance to CDK4/6 Inhibitors in Estrogen Receptor-Positive Breast Cancer. *Int J Mol Sci* 2021;**22**(22) doi 10.3390/ijms222212292.
6. Martin JM, Handorf EA, Montero AJ, Goldstein LJ. Systemic Therapies Following Progression on First-line CDK4/6-inhibitor Treatment: Analysis of Real-world Data. *Oncologist* 2022;**27**(6):441-6 doi 10.1093/oncolo/oyac075.
7. Sledge GW, Jr., Toi M, Neven P, Sohn J, Inoue K, Pivot X, *et al.* The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial. *JAMA Oncol* 2020;**6**(1):116-24 doi 10.1001/jamaoncol.2019.4782.
8. Vonderheide RH, Domchek SM, Clark AS. Immunotherapy for Breast Cancer: What Are We Missing? *Clin Cancer Res* 2017;**23**(11):2640-6 doi 10.1158/1078-0432.CCR-16-2569.
9. Swoboda A, Nanda R. Immune Checkpoint Blockade for Breast Cancer. *Cancer Treat Res* 2018;**173**:155-65 doi 10.1007/978-3-319-70197-4_10.
10. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, *et al.* Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. *Nat Med* 2007;**13**(9):1050-9 doi 10.1038/nm1622.
11. Tesniere A, Schlemmer F, Boige V, Kepp O, Martins I, Ghiringhelli F, *et al.* Immunogenic death of colon cancer cells treated with oxaliplatin. *Oncogene* 2010;**29**(4):482-91 doi 10.1038/onc.2009.356.
12. Jhunjhunwala S, Hammer C, Delamarre L. Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion. *Nat Rev Cancer* 2021;**21**(5):298-312 doi 10.1038/s41568-021-00339-z.
13. Yamauchi T, Moroishi T. Hippo Pathway in Mammalian Adaptive Immune System. *Cells* 2019;**8**(5) doi 10.3390/cells8050398.
14. Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, *et al.* Activation of the NLRP3 inflammasome in dendritic cells induces IL-1 β -dependent adaptive immunity against tumors. *Nat Med* 2009;**15**(10):1170-8 doi 10.1038/nm.2028.

15. Nistico P, Capone I, Palermo B, Del Bello D, Ferraresi V, Moschella F, *et al.* Chemotherapy enhances vaccine-induced antitumor immunity in melanoma patients. *Int J Cancer* 2009;**124**(1):130-9 doi 10.1002/ijc.23886.
16. Chocarro L, Blanco E, Zuazo M, Arasanz H, Bocanegra A, Fernandez-Rubio L, *et al.* Understanding LAG-3 Signaling. *Int J Mol Sci* 2021;**22**(10) doi 10.3390/ijms22105282.
17. Goldberg MV, Drake CG. LAG-3 in Cancer Immunotherapy. *Curr Top Microbiol Immunol* 2011;**344**:269-78 doi 10.1007/82_2010_114.
18. Triebel F, Hacene K, Pichon MF. A soluble lymphocyte activation gene-3 (sLAG-3) protein as a prognostic factor in human breast cancer expressing estrogen or progesterone receptors. *Cancer Lett* 2006;**235**(1):147-53 doi 10.1016/j.canlet.2005.04.015.
19. Brignone C, Grygar C, Marcu M, Schakel K, Triebel F. A soluble form of lymphocyte activation gene-3 (IMP321) induces activation of a large range of human effector cytotoxic cells. *J Immunol* 2007;**179**(6):4202-11.
20. Brignone C, Escudier B, Grygar C, Marcu M, Triebel F. A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma. *Clin Cancer Res* 2009;**15**(19):6225-31 doi 10.1158/1078-0432.CCR-09-0068.
21. Brignone C, Grygar C, Marcu M, Perrin G, Triebel F. IMP321 (sLAG-3), an immunopotentiator for T cell responses against a HBsAg antigen in healthy adults: a single blind randomised controlled phase I study. *J Immune Based Ther Vaccines* 2007;**5**:5 doi 10.1186/1476-8518-5-5.
22. Brignone C, Grygar C, Marcu M, Perrin G, Triebel F. IMP321 (sLAG-3) safety and T cell response potentiation using an influenza vaccine as a model antigen: a single-blind phase I study. *Vaccine* 2007;**25**(24):4641-50 doi 10.1016/j.vaccine.2007.04.019.
23. Dirix L, Triebel F. AIPAC: a Phase IIb study of eftilagimod alpha (IMP321 or LAG-3Ig) added to weekly paclitaxel in patients with metastatic breast cancer. *Future Oncol* 2019;**15**(17):1963-73 doi 10.2217/fon-2018-0807.
24. Duhoux FP, Jager A, Dirix LY, Huizing MT, Jerusalem GHM, Vuylsteke P, *et al.* Combination of paclitaxel and a LAG-3 fusion protein (eftilagimod alpha), as a first-line chemoimmunotherapy in patients with metastatic breast carcinoma (MBC): Final results from the run-in phase of a placebo-controlled randomized phase II. *Journal of Clinical Oncology* 2018;**36**(15_suppl):1050- doi 10.1200/JCO.2018.36.15_suppl.1050.
25. Ehinger A, Malmstrom P, Bendahl PO, Elston CW, Falck AK, Forsare C, *et al.* Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013. *Acta Oncol* 2017;**56**(1):68-74 doi 10.1080/0284186X.2016.1237778.
26. Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, Andre F, *et al.* 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4) dagger. *Ann Oncol* 2018;**29**(8):1634-57 doi 10.1093/annonc/mdy192.
27. Berben L, Floris G, Kenis C, Dalmaso B, Smeets A, Vos H, *et al.* Age-related remodelling of the blood immunological portrait and the local tumor immune response in patients with luminal breast cancer. *Clin Transl Immunology* 2020;**9**(10):e1184 doi 10.1002/cti2.1184.
28. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, *et al.* Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. *N Engl J Med* 2007;**357**(26):2666-76 doi 10.1056/NEJMoa072113.

29. Miles D, Cameron D, Hilton M, Garcia J, O'Shaughnessy J. Overall survival in MERiDiAN, a double-blind placebo-controlled randomised phase III trial evaluating first-line bevacizumab plus paclitaxel for HER2-negative metastatic breast cancer. *Eur J Cancer* 2018;**90**:153-5 doi 10.1016/j.ejca.2017.10.018.
30. Cherny NI, Sullivan R, Dafni U, Kerst JM, Sobrero A, Zielinski C, *et al.* A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). *Ann Oncol* 2015;**26**(8):1547-73 doi 10.1093/annonc/mdv249.
31. Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsy P, Loibl S, *et al.* De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. *Ann Oncol* 2017;**28**(8):1700-12 doi 10.1093/annonc/mdx308.

TABLES

Table 1. Baseline patient and disease characteristics in the randomized patient population.

n, %	Efti + Paclitaxel n = 114	Placebo + Paclitaxel n = 112	Overall N = 226
Age, yrs			
Median (range)	58 (24–87)	61 (35–79)	60 (24–87)
<65	76 (66.7)	71 (63.4)	147 (65.1)
BMI, median (range)	24.7 (18.1–48.1)	24.9 (15.4–44.5)	24.7 (15.4–48.1)
ECOG PS 0	69 (60.5)	70 (62.5)	139 (61.5)
ECOG PS 1	44 (38.6)	42 (37.5)	86 (38.1)
Visceral disease	103 (90.4)	104 (92.9)	207 (91.6)
Luminal, % ^a			
A-like	34.1	36.7	35.5
B-like	48.8	49.4	49.1
Other	17.1	13.8	15.4
Monocytes <0.25/nL	25 (21.9)	22 (19.8)	47 (20.9)
LDH >250 U/L	74 (65.5)	81 (73.0)	155 (69.2)
Prior surgery	92 (80.7)	94 (83.9)	186 (82.3)
Prior radiotherapy	87 (76.3)	84 (77.7)	174 (77.0)
Prior systemic therapies			
Any	106 (93.0)	108 (96.4)	214 (94.7)
≥3	19 (16.7)	28 (25.0)	47 (20.8)
Prior adjuvant therapy	85 (74.6)	81 (72.3)	166 (73.5)
Prior therapy for metastatic disease	78 (68.4)	80 (71.4)	158 (69.9)
Prior taxanes (adjuvant)	51 (44.7)	43 (38.4)	94 (41.6)
Prior CDK4/6i	50 (44.6)	50 (43.9)	100 (44.2)
Prior endocrine therapy	103 (90.4)	104 (92.9)	207 (91.6)
Endocrine resistant ^b	85 (82.5)	89 (85.6)	174 (84.1)
Last therapy prior to inclusion			
None	6 (5.3)	4 (3.6)	10 (4.4)
Adjuvant/curative	25 (21.9)	22 (19.6)	47 (20.8)
Palliative	83 (72.8)	86 (76.8)	169 (74.8)

Representativeness of study participants is provided in Supplemental Table 2.

Abbreviations: BMI, body mass index; CDKi, cyclin-dependent kinase inhibitor treatment; ECOG, Eastern Cooperative Oncology Group; Efti, eftilagimod alpha; LDH, lactate dehydrogenase.

^aRetrospective central assessment performed on available and evaluable primary or metastatic tissues (n = 169) classified using PgR and Ki67 index according to St. Gallen International Expert Consensus guidelines (31).

^bDefined according to the 4th ESO-ESMO International Consensus Guidelines (26).

Table 2. Treatment-emergent adverse events of any grade in >15% of patients and/or of grade ≥3 in >5% of patients in either arm in the safety population.

Event, n (%)	Efti + Paclitaxel (n = 114)		Placebo + Paclitaxel (n = 112)	
	Any Grade	Grade ≥3	Any Grade	Grade ≥3
Fatigue	53 (46.5)	2 (1.8)	55 (49.1)	2 (1.8)
Alopecia	46 (40.4)	0	56 (50.0)	0
Nausea	44 (38.6)	3 (2.6)	40 (35.7)	0
Diarrhea	33 (28.9)	1 (0.9)	41 (36.6)	1 (0.9)
GGT increased	25 (21.9)	23 (20.2)	34 (30.4)	33 (29.5)
Peripheral neuropathy	23 (20.2)	0	28 (25.0)	1 (0.9)
Injection site reaction	39 (34.2)	0	4 (3.6)	0
Peripheral sensory neuropathy	21 (18.4)	0	22 (19.6)	2 (1.8)
Neutropenia	22 (19.3)	18 (15.8)	21 (18.8)	16 (14.3)
Cough	20 (17.5)	0	22 (19.6)	0
Constipation	20 (17.5)	0	20 (17.9)	0
Headache	21 (18.4)	0	17 (15.2)	1 (0.9)
Injection site erythema	35 (30.7)	1 (0.9)	2 (1.8)	0
Asthenia	16 (14.0)	1 (0.9)	20 (17.9)	0
Dyspnea	16 (14.0)	2 (1.8)	20 (17.9)	4 (3.6)
AST increased	16 (14.0)	10 (8.8)	18 (16.1)	13 (11.6)
Anemia	18 (15.8)	7 (6.1)	16 (14.3)	1 (0.9)
Peripheral edema	8 (7.0)	0	19 (17.0)	1 (0.9)
Blood ALP increased	9 (7.9)	5 (4.4)	14 (12.5)	10 (8.9)
ALT increased	10 (8.8)	5 (4.4)	12 (10.7)	7 (6.3)
WBC count decreased	5 (4.4)	4 (3.5)	11 (9.8)	7 (6.3)
Lymphocyte count decreased	3 (2.6)	3 (2.6)	7 (6.3)	7 (6.3)
Neutrophil count decreased	2 (1.8)	2 (1.8)	6 (5.4)	6 (5.4)
Hypophosphatemia	2 (1.8)	1 (0.9)	9 (8.0)	9 (8.0)
Hypertension	14 (12.3)	7 (6.1)	11 (9.8)	3 (2.7)

Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyl aminotransferase; WBC, white blood cell.

LEGENDS TO FIGURES

Figure 1. (A) Progression-free survival by blinded independent central review and **(B)** overall survival in the efficacy evaluable population by treatment arm. CI, confidence interval; HR, hazard ratio.


Figure 2. Treatment effect by subgroup **(A)** Progression free survival by blinded independent central review. **(B)** Overall survival. Efti, eftilagimod alpha; CI, confidence interval.

Figure 3. (A) Mean of peripheral blood CD8⁺ T-cell count over time from randomization stage immuno-monitoring subject subset and **(B)** observed correlation between CD8⁺ T-cell count at baseline, 3 and 6 months and overall survival among patients in the 30 mg efti plus paclitaxel and placebo plus paclitaxel treatment arms. **(C)** Mean change from baseline in absolute lymphocyte count (ALC) over time by OS status and treatment arm in randomization stage. Timepoints with ≥8 patients per subgroup are displayed. **(D-E)** Kaplan-Meier plot of OS of subgroup of efti **(D)** and placebo **(E)** treatment arms by ALC change from baseline (cut-off = $0.2 \times 10^9/L$ of blood within 9 weeks of treatment). Median OS = 18.2 months.

* indicates significant ($P < 0.05$) difference between treatment arms (black) and between OS status in eftilagimod arm (red).

CI, confidence interval; HR, hazard ratio; OS, overall survival; Efti, eftilagimod alpha.


A



No. of patients at risk (censored)





Placebo	112 (0)	76 (12)	42 (26)	17 (36)	3 (42)	1 (44)	0 (45)
Efti	114 (0)	88 (13)	51 (27)	17 (36)	4 (42)	2 (43)	0 (45)

B




No. of patients at risk (censored)

Placebo	112 (0)	98 (1)	70 (1)	52 (2)	38 (4)	21 (13)	11 (22)	3 (28)	1 (28)
Efti	114 (0)	103 (3)	72 (3)	62 (3)	45 (6)	24 (18)	15 (24)	6 (29)	0 (33)



Downloaded from <http://ascopubs.org/clinicaltrials/article-pdf/10.1158/1078-0432.CCR-23-1173> by guest on November 10, 2023



Downloaded from <http://ascopubs.org/clinccancer/article-pdf/doi/10.1158/1078-0432.CCR-23-1733/381144/cr-23-1733.pdf> on November 2023